Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.
/PRNewswire/ Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes.
/PRNewswire/ Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes.